Agnès Ducoulombier

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Fernanda Mosele, Élise Deluche, Amélie Lusque et al. · Nature Medicine · 2023 · 318 citations · Full text

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 214 citations

Gortec 2014-01 Tpextreme, Neoadjuvant Therapy, Medicine +11

Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Véronique Dièras, Élise Deluche, Amélie Lusque et al. · Cancer Research · 2022 · 107 citations

Abstract Pd8-02, Breast Oncology, Immunology +27

Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors

Sabrina Croce, Agnès Ducoulombier, Agnès Ribeiro et al. · Modern Pathology · 2018 · 68 citations · Full text

Efficient Tool, Functional Genomics, Engineering +12

LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial

M.F. Mosele, Amélie Lusque, Véronique Dièras et al. · Annals of Oncology · 2022 · 48 citations